본문 바로가기
KERD
논문KCI 등재

갑상선분화암의 수술 후 추적관찰: 갑상선글로불린 검사의 이용

Postoperative Follow-Up of Differentiated Thyroid Cancer: Use of Thyroglobulin Assay

김태용
대한갑상선학회 (Korean Thyroid Association)|2012.05|International Journal of Thyroidology|제5권 제1호|pp. 20-24

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Thyroid갑상선갑상선암Biological markersThyroglobulinThyroid neoplasm생물표지자갑상선글로불린.
주제분류의학일반

초록

Stimulated thyroglobulin measured 6-12 months after thyroidectomy and radioactive iodine remnant ablation is a very useful guidance for risk-stratification. Thus, this parameter should be a main variable of strategy for follow-up in such patients. Serum Tg and TgAb measurement at the time of ablation just after total thyroidectomy could give a helpful data supporting stimulated Tg measured 6-12 months after radioactive iodine remnant ablation and should be considered in your own follow-up strategies.

Abstract

Stimulated thyroglobulin measured 6-12 months after thyroidectomy and radioactive iodine remnant ablation is a very useful guidance for risk-stratification. Thus, this parameter should be a main variable of strategy for follow-up in such patients. Serum Tg and TgAb measurement at the time of ablation just after total thyroidectomy could give a helpful data supporting stimulated Tg measured 6-12 months after radioactive iodine remnant ablation and should be considered in your own follow-up strategies.

참고문헌 (34)

  1. Eustatia-Rutten CF, "Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis", Clin Endocrinol (Oxf), 61(1), pp.61~74 (2004)
  2. Mazzaferri EL, "A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma", J Clin Endocrinol Metab, 88(4), pp.1433~1441 (2003)
  3. Nascimento C, "Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level", Endocr Relat Cancer, 18(2), pp.29~40 (2011)
  4. Pacini F, "Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment", J Clin Endocrinol Metab, 87(4), pp.1499~1501 (2002)
  5. Toubeau M, "Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer", J Nucl Med, 45(6), pp.988~994 (2004)
  6. Menendez Torre E, "Prognostic value of thyroglobulin serum levels and 131I wholebody scan after initial treatment of low-risk differentiated thyroid cancer", Thyroid, 14(4), pp.301~306 (2004)
  7. Cailleux AF, "Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?", J Clin Endocrinol Metab, 85(1), pp.175~178 (2000)
  8. Schlumberger M, "Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma", Eur J Endocrinol, 138(3), pp.249~252 (1998)
  9. Baloch Z, "Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease", Thyroid, 13(1), pp.3~126 (2003)
  10. Pacini F, "European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium", Eur J Endocrinol, 154(6), pp.787~803 (2006)
  11. Cooper DS, "Management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 16(2), pp.109~142 (2006)
  12. Pacini F, "Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome", Acta Endocrinol (Copenh), 119(3), pp.373~380 (1988)
  13. Rubello D, "Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer", J Endocrinol Invest, 13(9), pp.737~742 (1990)
  14. Kumar A, "Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma", Thyroid, 4(2), pp.199~202 (1994)
  15. Spencer CA, "Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 83(4), pp.1121~1127 (1998)
  16. Chiovato L, "Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens", Ann Intern Med, 139(5 Pt 1), pp.346~351 (2003)
  17. Rubello D, "Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study", J Nucl Med, 33(8), pp.1478~1480 (1992)
  18. Adil A, "Frequency and clinical importance of anti-Tg autoantibodies (ATG)", J Coll Physicians Surg Pak, 13(9), pp.504~506 (2003)
  19. Chung JK, "Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation", Clin Endocrinol (Oxf), 57(2), pp.215~221 (2002)
  20. Quevedo I, "Anti thyroglobulin antibodies in the follow up of patients with differentiated thyroid cancer: residual or relapsing disease markers?", Rev Med Chil, 130(2), pp.167~172 (2002)
  21. Gorges R, "Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy", Eur J Endocrinol, 153(1), pp.49~55 (2005)
  22. 김정민, "Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 93(12), pp.4683~4689 (2008), ENDOCRINE SOC
  23. Haugen BR, "A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer", J Clin Endocrinol Metab, 84(11), pp.3877~3885 (1999)
  24. Pacini F, "Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma", J Clin Endocrinol Metab, 86(12), pp.5686~5690 (2001)
  25. Cooper DS, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
  26. Pacini F, "Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients", J Clin Endocrinol Metab, 86(9), pp.4092~4097 (2001)
  27. Pineda JD, "Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan", J Clin Endocrinol Metab, 80(5), pp.1488~1492 (1995)
  28. Koh JM, "Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study", Clin Endocrinol (Oxf), 58(4), pp.421~427 (2003)
  29. Fatourechi V, "Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer", J Clin Endocrinol Metab, 87(4), pp.1521~1526 (2002)
  30. Kim WG, "Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan", J Clin Endocrinol Metab, 95(3), pp.1169~1173 (2010)
  31. Baudin E, "Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients", J Clin Endocrinol Metab, 88(3), pp.1107~1111 (2003)
  32. Chao M, "Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan", Clin Oncol (R Coll Radiol), 22(6), pp.438~447 (2010)
  33. Kloos RT, "Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values", J Clin Endocrinol Metab, 95(12), pp.5241~5248 (2010)
  34. Kim TY, "Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 90(3), pp.1440~1445 (2005)

관련 논문AI추천

분자생물학적 표지자를 이용한 갑상선암 환자의 맞춤형 추적관찰김태용대한갑상선학회 · International Journal of Thyroidology2011 · 제4권 제2호Consideration of Serum Thyrotropin When Interpreting Serum Thyroglobulin Level in Patients with Differentiated Thyroid Cancer김춘영, 손승현, 안병철, 이상우, 이재태, 이창희, 정신영, 정주혜, 정지훈대한갑상선학회 · International Journal of Thyroidology2017 · 제10권 제1호갑상선암의 치료 지침김원배대한내과학회 · 대한내과학회지2009 · 제77권 제5호Serum Thyroglobulin Monitoring after Thyroid Lobectomy for Differentiated Thyroid Carcinoma: a Narrative Review and Contemporary Guidelines구본석, 김지원, 문성준, 이수민대한갑상선학회 · International Journal of Thyroidology2025 · 제18권 제2호대한갑상선학회 갑상선분화암 진료권고안; Part II. 갑상선분화암의 추적 2024강호철, 김미진, 김보현, 김선욱, 나동규, 박영주, 방지인, 서영덕, 송영신, 오소원, 이민경, 이상우, 이은경, 이지예, 임동준, 정아리, 정윤재, 홍채문대한갑상선학회 · International Journal of Thyroidology2024 · 제17권 제1호The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancerHee Kyung Kim, Ho-Cheol Kang, Jee Hee Yoon, Jin Seong Cho, Seong Young Kwon, Su Woong Yoo대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제5호

이 간행물의 다른 논문 (12건)

갑상선 수술의 비전: 과거와 현재, 그리고 미래윤여규, 최준영pp. 1-5갑상선질환 환자의 방사성요오드 치료시 방사선 안전관리정웅윤, 김병일, 김인주, 이재태, 강성민, 범희승, 정재훈, 이가희pp. 6-14갑상선분화암의 수술 후 감시: 초음파 관점곽진영pp. 15-19장기적인 TSH 억제가 심혈관계에 미치는 영향송종민pp. 25-30장기간 TSH 억제가 골격계에 미치는 효과김민희, 강무일pp. 31-38
원문 보기